The drug development crisis: efficiency and safety.
Despite advancements in genetics, chemistry, and protein engineering, recent years have seen fewer approvals of new drugs, increases in development costs, and high-profile drug withdrawals. This article focuses on technologic methods for improving drug development efficiency. These technologies include high-content cell screening, expression profiling, mass spectroscopy, mouse models of disease, and a post-launch screening program that enables investigations of adverse drug effects. Implementation of these new technologies promises to improve performance in drug development and safety.
Caskey
C Thomas
CT
Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA. C.Thomas.Caskey@uth.tmc.edu
D000818:Animals; D020811:Biomedical Technology / Q000379:methods*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D017277:Drug Approval / Q000458:organization & administration*; D004353:Drug Evaluation, Preclinical; D005434:Flow Cytometry; D020869:Gene Expression Profiling; D006801:Humans; D013058:Mass Spectrometry; D051379:Mice; D014481:United States